Camsirubicin
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00710125)
Timeline
Indications
Studied for
Mechanism of action
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc2c1C(=N)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(CCO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1- Mol. weight
- 528.56 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095173 ↗
Also known as
- 5-imino-13-deoxydoxorubicin
- gpx-150
- gpx-150
- gpx-150
- gpx-150
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05043649 | Phase 1 | Sep 30, 2021 | Monopar Therapeutics |
| NCT02267083 | Phase 2 | Jan 7, 2015 | Gem Pharmaceuticals, University of Iowa |
| NCT00710125 | Phase 1 | Jan 1, 2008 | Gem Pharmaceuticals, University of Iowa |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gem Pharmaceuticals | For profit | 2 | 2 | 2 | 2008 |
| University of Iowa | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Monopar Therapeutics | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1